Бритомар

Quick links to important sections

Бритомар

Selected form

Method of action: Diuretic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Бритомар

What is Бритомар? (Torasemide)

Property Description
Active ingredient Torasemide (INN)
Form Tablet (Oral), Solution for injection (Intravenous)
Pharmacological class Loop diuretic, Antihypertensive agent
General purpose Management of fluid retention and high blood pressure
Origin Synthetic compound (Pyridinesulfonylurea derivative)

Active Ingredient, Classification, and Composition

Бритомар is the designation for a synthetic, single-component, prescription-only medicinal preparation centered on the active ingredient Torasemide (INN). This compound is a derivative of the pyridinesulfonylurea chemical class, a structure utilized in pharmacology due to its specific targeting mechanism. Бритомар is formally classified as a loop diuretic, a type characterized by its fluid-mobilizing capability, and is also recognized as an antihypertensive agent. Torasemide is characterized by its potency and onset of action compared to earlier generations of diuretics, and it serves as a tool for volume management.

Pharmaceutical Forms and General Therapeutic Purpose

The medicine is supplied in a tablet form for oral administration and as a sterile solution for injection contained in ampoules for intravenous use, providing options for various clinical needs, from routine maintenance to acute situations. The primary purpose of Torasemide is to modulate the body's fluid balance by acting on the kidneys to promote the excretion of salt and water. This function is intended to reduce excess fluid, which is instrumental in alleviating the physical accumulation of fluid known as edema, particularly that associated with chronic heart failure. This action is utilized in the management of conditions characterized by high blood pressure, contributing to the overall control of hypertension.

What side effects are possible with Бритомар?

Official Safety Profile

The following safety information for Britomart (Mirabegron) is based exclusively on official governmental regulatory documents, structured by adverse event frequency and System-Organ Class (SOC).

Frequency-Classified Adverse Reactions

Classification Examples of Reactions
Very Common (Affects 1 in 10) Urinary tract infection (UTI)
Common (Affects 1 in 100) Tachycardia (increased heart rate), Headache, Hypertension (increased blood pressure), Nausea, Constipation, Dizziness
Uncommon (Affects 1 in 1,000) Palpitations, Rash, Urticaria, Pruritus, Dyspepsia, Cystitis, Peripheral oedema, Increased liver enzymes (ALT, AST)
Rare (Affects 1 in 10,000) Angioedema, Anaphylactic reaction, Leukocytoclastic vasculitis

Serious and Clinically Significant Adverse Reactions

Official labels document the risk of severe reactions that require immediate attention. These include Angioedema (swelling of the face, lips, tongue, or larynx, potentially affecting breathing) and Anaphylactic Reaction. A key cardiovascular warning relates to severe, uncontrolled hypertension (blood pressure 180/110 mmHg), which is a contraindication for use. Acute urinary retention is also documented, particularly in patients with pre-existing bladder outlet obstruction or when the medicine is used with other specific drugs.

Safety Restrictions and Considerations

The medicine is contraindicated (should not be used) in patients with severe uncontrolled hypertension, severe kidney impairment (e.g., those requiring dialysis), and severe liver impairment. Caution is advised when prescribing this medicine with other drugs that are significantly metabolized by the CYP2 D6 enzyme, as this may increase exposure to those drugs. Regulatory documents recommend periodic monitoring of blood pressure, especially in patients who already have hypertension.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Бритомар (Torasemide) is officially documented to lead to uncontrolled, marked diuresis, resulting in severe hypovolemia (low blood volume) and dehydration. The physiological manifestations listed in regulatory documents include hypotension (low blood pressure), somnolence, confusion, and gastrointestinal disturbances. Laboratory findings associated with overdose include hyponatremia (low sodium), hypokalemia (low potassium), and hemoconcentration.

When to Seek Urgent Medical Attention

Immediate medical attention is required for any suspected overdose due to the high risk of life-threatening circulatory consequences. Severe fluid and electrolyte loss can lead to circulatory collapse and is documented as potentially resulting in thrombosis, embolism, cardiac ischaemia, or cerebral ischaemia.

Regulatory Management Statements

Official management procedures include the immediate withdrawal of the drug and the simultaneous replacement of lost fluid and electrolytes. Treatment is strictly symptomatic and supportive, as regulatory labeling confirms that no specific antidote is known for Torasemide toxicity. Close monitoring of the patient's fluid status, serum electrolytes, and kidney function is required. Special overdose considerations apply to elderly patients and individuals with hepatic cirrhosis, who face an increased risk of severe complications.

Therapeutic Uses of Бритомар

What Бритомар Treats: Main Uses and Benefits

Бритомар (Torasemide) is a therapeutic option applied across several domains where the physiological state may be affected by the accumulation of fluid or elevated blood pressure. The medication is indicated for the management of symptoms related to systemic imbalance and cardiovascular strain.


Relief from Systemic Fluid Overload and Edema

This domain covers the use of Бритомар in addressing symptoms related to physical effects caused by excess fluid retention. It is applicable in conditions characterized by periods of heightened symptoms, including noticeable swelling in the limbs (edema) and ascites (abdominal fluid), associated with heart, kidney, or liver disease. The medication addresses symptoms that create physiological strain, which is intended to assist with maintaining functional stability.

Management of Congestive Symptoms and Blood Pressure

Бритомар is also relevant in clinical settings marked by cardiovascular strain and pulmonary congestion (fluid in the lungs), both of which are symptomatic manifestations of heart failure. It is used for managing symptom clusters by reducing the circulating fluid volume, thereby addressing symptoms such as shortness of breath and supporting the management of high blood pressure. This supports physiological balance during symptomatic phases.

The medication is utilized to help with complex symptomatic burdens, such as significant fluid retention alongside elevated systemic pressure, including those related to fluid retention, congestive heart failure, renal disease, and hepatic cirrhosis, as well as hypertension.

Quick Fact: Relief for Edema and Congestion

Бритомар is utilized for the management of fluid-related symptoms that may interfere with routine activities during episodes of heightened discomfort.

Regulatory References

  1. NIH DailyMed Overview

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Бритомар (Torasemide) is officially permitted for use in the adult population (18 years and older) for labeled conditions such as edema associated with heart failure, renal disease, and hepatic cirrhosis. The medicine's use is strictly defined by regulatory eligibility criteria, with certain populations formally excluded.

Absolute Contraindications

Regulatory documents explicitly contraindicate the use of Torasemide in the following groups:

  • Patients with anuria (absence of urine production).
  • Individuals with known hypersensitivity to Torasemide or to sulfonylurea medicines.
  • Patients currently in a state of hepatic coma or pre-comatose states.
  • Patients with uncorrected, severe hypovolemia (low blood volume) or hypotension.

Restricted and Non-Recommended Use

Use is generally not recommended in pediatric patients (under 18 years) because safety and efficacy data have not been sufficiently established. Use is also not recommended during pregnancy and lactation (breastfeeding), as potential risks or excretion into human milk have not been definitively ruled out in official labeling. Caution and close monitoring are mandatory for older adults and patients with severe, but not anuric, renal impairment or severe hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration of Бритомар (torasemide) with specific medicinal products or product classes requires careful monitoring and, in some cases, dosage adjustments, based on official regulatory documentation.

Documented Interactions

Interacting Product Category Key Practical Constraint/Requirement
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) & High-Dose Salicylates May reduce the diuretic and antihypertensive effect; high risk of acute renal failure when co-administered in patients with impaired renal function.
Lithium Requires careful monitoring of lithium plasma concentrations and potential dose adjustment due to reduced renal clearance, increasing the risk of toxicity.
Angiotensin-Converting Enzyme (ACE) Inhibitors & ARBs May cause an initial severe drop in blood pressure, potentially requiring temporary discontinuation or dose reduction of torasemide when initiating combination therapy.
Digoxin Torasemide may increase the plasma concentration of digoxin, necessitating close monitoring.
Cholestyramine Requires a time separation of at least 1 hour between administration to prevent reduced absorption of torasemide.
Potassium-Sparing Diuretics & Corticosteroids Concurrent use may increase the risk of hypokalemia (low potassium levels).

Interaction Context

Official labeling defines the interaction structure based on both pharmacokinetic and pharmacodynamic mechanisms, focusing on effects like altered drug clearance, reduced absorption, and additive electrolyte imbalances. This profile emphasizes the critical need for close monitoring and procedural constraints, such as timed dosing separation, to mitigate risks associated with co-administration.

Mechanism of Action

Molecular Blockade in the Kidney's Loop of Henle

Torasemide (Бритомар) exerts its primary mechanism by competitive inhibition of the Na⁺/K⁺/2Cl⁻ cotransporter ( NKCC2), a critical protein located on the luminal side of the epithelial cells in the thick ascending limb of the renal tubules. This molecular action directly halts the reabsorption of a substantial fraction of filtered salt and water from the tubular fluid back into the circulation . This interference initiates a high rate of water flow toward the urinary system.


Cascade of Fluid Mobilization and Volume Regulation

By blocking NKCC2, the drug triggers a profound mechanistic cascade resulting in rapid natriuresis (sodium excretion) and subsequent diuresis (water excretion). This action sharply reduces the body's overall extracellular fluid volume, which is the core physiological mechanism that lessens the volume burden on the circulatory system, decreasing cardiac load.


Modulation of Systemic Vascular Resistance

The drug exhibits a secondary action by modulating vascular tone. Torasemide interferes with the vasoconstrictor action of Angiotensin II ( Ang II) on the smooth muscle cells of blood vessels, resulting in a reduction of systemic vascular resistance (afterload). This dual action on both volume and vessel tension determines the drug's resultant physiological effect on the circulatory system.

Dosage and Administration Information

How to Use Бритомар (Torasemide) — Standard Administration Overview

Torasemide is administered according to parameters that establish the route, timing, and dosage based on the condition being addressed.


Administration Protocol and Forms

Usage Entity General Parameters
Administration Route The medicine is available as an oral tablet for maintenance use and as a solution for injection for intravenous (IV) administration in acute settings.
Frequency & Timing Standard initial and maintenance regimens involve once daily administration. Oral tablets are typically taken in the morning and may be taken with or without food.
Tablet Preparation Tablets are intended to be swallowed whole with fluid and not chewed. The IV form is administered as a bolus or via continuous infusion.

Dosing and Adjustment Rules

Administration begins with a starting dose that is subsequently adjusted based on the observed clinical response. Dose titration for hypertension typically occurs after 4 to 6 weeks of initial treatment.

  • Hypertension: The initial daily dose is typically 5 mg, with a maximum maintenance dose of 10 mg.
  • Edema (Heart/Renal Failure): The initial daily dose is 10 mg or 20 mg. Doses may be increased for titration up to a maximum daily dose of 200 mg.
  • Population Nuances: For edema related to hepatic cirrhosis, a maximum daily dose of 40 mg is specified and is administered concomitantly with a potassium-sparing agent.

The medication is generally used for long-term management. Standard practice for a missed dose involves taking it when remembered unless the next dose is due, in which case the missed dose is skipped rather than doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Бритомар (Torasemide)


Evidence for Use in Managing Fluid Overload and Congestive Symptoms

Clinical evidence, including Randomized Controlled Trials (RCTs) and Systematic Reviews, has assessed research measuring changes in fluid retention (edema) and tracking the management of symptoms associated with Heart Failure, renal disease, and hepatic cirrhosis. Studies explored changes in outcomes related to physical discomfort and measures of total body weight. Researchers monitored how functional status and symptom severity evolved over defined time intervals in observed populations.

Findings describe patterns observed in the studies related to diuresis and natriuresis (fluid and salt excretion). Some trials reported changes in patient-reported outcomes describing perceived discomfort and changes in daily functioning. What remains uncertain is the consistency of the evidence regarding all-cause mortality rates across different studies. Long-term effects are not fully established based on the highest quality of research, as some evidence for clinical outcomes is derived from observational settings rather than strictly controlled designs. Therefore, the certainty related to these extended outcomes remains lower.


Evidence for Use in Essential Hypertension

Controlled Trials have evaluated the medicine’s role in the treatment of high blood pressure, detailing which blood pressure metrics and clinical goals were tracked by researchers. Studies explored the effect of the medicine on changes in Systolic and Diastolic Blood Pressure (SBP/DBP), including monitoring these changes over a 24-hour period. Research evaluated whether patients could achieve defined pressure control targets during the study period.

Findings describe patterns related to the effect on blood pressure metrics observed in the studies. Data show patterns related to use as a single treatment and in combination regimens with other high blood pressure medications. A key limitation here is that the main controlled trials in this domain do not typically use cardiovascular events or mortality as primary outcomes. Comparative evidence is lacking for demonstrating long-term cardiovascular event risk reduction when the medicine is used alone to manage high blood pressure.

Frequently Asked Questions (FAQ)

Common questions about Бритомар (FAQ)


Q: Does Бритомар cause extreme tiredness or fatigue?

Fatigue or weakness is not generally listed as a common, distinct side effect in the official product information. However, because this medicine affects fluid and electrolyte balance in the body, symptoms like weakness or tiredness may occur if these balances are disrupted.


Q: Are there any common but mild side effects of Бритомар I should know about?

According to regulatory documents, commonly reported effects include headache, dizziness, nausea, and constipation. These effects may be temporary as your body adjusts to the medication.


Q: Can Бритомар affect kidney function in the long run?

Official labeling warns about the risk of worsening or acute renal failure, particularly in patients who have existing risk factors. For this reason, monitoring of kidney function may be necessary during long-term treatment.


Q: Why do some people experience dizziness when starting Бритомар?

Dizziness is a commonly reported side effect, according to regulatory documents. It often results from the drug's effect of reducing fluid volume, which can cause an initial drop in blood pressure (hypotension) when treatment is first started.


Q: Can taking too much potassium while on Бритомар be dangerous?

This medicine primarily causes low potassium (hypokalemia). However, taking excessive potassium supplements presents a risk for hyperkalemia (high potassium), which can be dangerous. Monitoring of serum electrolytes is recommended periodically.


Q: Does Бритомар interact with common over-the-counter pain relievers?

Official drug interaction information warns that this medicine interacts with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes many common over-the-counter pain relievers. This combination may potentially reduce the diuretic effect and increase the risk of renal problems.


Q: What happens if I accidentally miss a dose of Бритомар?

Official instructions state that if you remember a missed dose, you may take it. However, if it is already close to the time of your next scheduled dose, it is generally recommended to skip the missed dose entirely and resume your regular schedule without doubling the dose.


Q: Is Бритомар safe for elderly patients with hypertension?

Official information advises caution for use in older adults because they may metabolize the drug more slowly. If prescribed, closer monitoring and potential dose adjustments are often advised.


Q: Can younger adults or teens be prescribed Бритомар?

The safety and effectiveness of this medicine have not been established in patients under 18 years of age. Therefore, regulatory guidelines generally do not recommend its use in the pediatric population.


Q: Is Бритомар safe to take while breastfeeding?

Official labeling states that it is not known whether the medicine passes into human milk. Due to this uncertainty, regulatory documents generally do not recommend its use during lactation.


Q: What is the connection between Бритомар and gout?

The official product label documents that this medicine can sometimes cause an increase in uric acid levels (asymptomatic hyperuricemia). This change in uric acid may, in rare instances, trigger episodes of gout.


Q: What is the maximum amount of time someone typically stays on Бритомар?

The medication is typically used for long-term management of chronic conditions, such as hypertension or edema. The specific duration of use is determined by the prescribing health professional.


Q: What research supports the use of Бритомар for cardiovascular risk reduction?

Official studies have not demonstrated that this medicine, when used alone for hypertension, reduces the risk of major cardiovascular events or mortality in controlled trials. Its primary benefit is in lowering blood pressure and managing fluid volume.


Q: Is it safe to drive or operate machinery after taking Бритомар?

Because the medicine can cause side effects like dizziness, lightheadedness, or blurred vision, caution is advised when driving or operating machinery until you know how the medication affects you.


Q: Why is Бритомар sometimes prescribed for people without hypertension?

In addition to high blood pressure, the medicine is officially indicated for treating edema (fluid retention) associated with severe conditions like heart failure, kidney disease, or liver cirrhosis, which can occur independent of high blood pressure.


Q: Is it true that Бритомар has a long duration of action?

According to pharmacokinetics data, the duration of its diuretic action is approximately 6 to 8 hours. This duration supports its once-daily dosing regimen.


Q: How often is a follow-up visit needed when starting Бритомар?

Regulatory guidance recommends that volume status, kidney function, and electrolytes be monitored periodically after starting treatment. The specific frequency of visits or testing is determined by the professional managing the treatment.


Q: What are the signs that Бритомар might not be working for me?

If prescribed for fluid retention, signs of ineffectiveness could include a lack of increased urination or no improvement in swelling. For hypertension, failure to achieve the desired lowering of blood pressure would suggest the medicine may not be working as intended.


Q: Does taking Бритомар cause any changes in mood or anxiety?

Official adverse event reports mention that the medicine can sometimes lead to central nervous system effects, including feelings of nervousness or anxiety.


Q: Can people with diabetes safely take Бритомар?

Caution is advised for people with diabetes. Regulatory warnings indicate that the medication has the potential to cause an increase in blood glucose levels (hyperglycemia). Monitoring of blood sugar is recommended regularly during treatment.


Q: Is it normal for my blood sugar to be slightly higher while on Бритомар?

Yes, official warnings note that the medication has the potential to cause an increase in blood glucose levels, a condition known as hyperglycemia. Therefore, your blood sugar may be slightly higher while on this medicine.


Q: Is there a link between Бритомар and hearing loss?

Yes, regulatory labels warn about the risk of ototoxicity, which can manifest as tinnitus (ringing in the ears) or hearing loss. This is a known, though often reversible, risk for this class of diuretics.


Q: Do other medications need to be adjusted when starting Бритомар?

Yes, dose adjustments are often necessary for other medications when starting this treatment. This includes drugs like Lithium and Digoxin, or medications metabolized by certain liver enzymes, to prevent altered effects or toxicity.


Q: Is it safe to use electrolyte drinks while on Бритомар?

Because this medicine significantly affects the body’s electrolyte balance, any product, including electrolyte drinks, that adds large amounts of potassium or other salts should be used with caution. Monitoring is important to avoid potentially serious imbalances.


Q: Can alcohol consumption be dangerous while taking Бритомар?

Yes, official drug interaction information indicates that consuming alcohol while taking this medicine can be unsafe. The two can have an additive effect in lowering your blood pressure, which may lead to symptoms like dizziness or lightheadedness.

How should Бритомар be stored and disposed of?

How to Store and Dispose of Бритомар (Torasemide)

The official labeling for Torasemide specifies mandatory storage conditions for both the tablets and the injection solution. The medication must be kept at controlled room temperature, typically 15 C to 30 C (59 F to 86 F), and must be kept from freezing.

Handling and Protection

Torasemide tablets require protection from the environment, mandating storage in a tightly closed container away from excessive heat, moisture, and direct light. Crucially, the medication must be stored out of the reach and sight of children.

Disposal Requirements

The injection solution ampuls are single-use containers; any unused portion must be discarded after opening. Disposal of all expired or unused Torasemide must be carried out in accordance with local and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Бритомар found in:

A-Z Index: